Labcorp announces partnership for colorectal cancer trials

Labcorp Partners for Colorectal Cancer Genetic Testing Study

Labcorp has partnered with the Alliance for Clinical Trials in Oncology for a new national, multi-centre study sponsored by the National Cancer Institute (NCI). The study aims to expand access to genetic testing for patients newly diagnosed with colorectal cancer (CRC) and their at-risk first-degree relatives. It will assess how direct outreach by healthcare providers can improve participation in cascade genetic testing and examine the influence of multigene panel test results on treatment and care decisions for CRC patients. Labcorp will serve as the exclusive genetic testing provider, utilizing its Invitae platform across study sites in the US and Puerto Rico.

• The core objective of the collaboration is to address the critical gap in genetic testing for inherited cancer risks. The study specifically investigates whether direct outreach from healthcare providers can significantly increase the uptake of cascade genetic testing among first-degree relatives of colorectal cancer patients, many of whom may carry inherited cancer-related variants. This initiative aims to generate real-world evidence on effective strategies for connecting families to essential genetic testing and follow-up care.
• Beyond cascade testing, the study will thoroughly assess the impact of multigene panel test results on the treatment and care decisions for individuals newly diagnosed with colorectal cancer. This aspect of the trial seeks to understand how comprehensive genetic information can inform and optimize clinical management, potentially leading to more personalized and effective therapeutic strategies for these patients.
• Labcorp is positioned as the exclusive genetic testing provider for this national, multi-centre study, leveraging its Invitae testing platform. The trial is led and conducted by the Alliance for Clinical Trials in Oncology within the NCI National Clinical Trials Network, encompassing academic medical centers, community oncology health systems, and NCI-designated cancer centers across the US, including Puerto Rico. This broad collaboration underscores a concerted effort to integrate genetics-based research into cancer care.

The Unmet Need for Cascade Genetic Testing in CRC

Recent literature highlights significant treatment gaps and underserved populations in colorectal cancer care. Despite advances in targeted therapies and immunotherapies, substantial challenges persist in achieving optimal outcomes across diverse patient populations. Multiple research initiatives are focusing on addressing these critical unmet needs.

• Treatment-resistant populations face limited options as CRC cells often exhibit resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy interventions, with substantial proportions developing refractory disease despite conventional therapies

• Microsatellite stable (MSS) patients remain underserved as immunotherapy shows limited effectiveness in this population, while immune checkpoint inhibitors demonstrate high efficacy (>90% response) only in the smaller subset with mismatch repair deficiency (dMMR) or microsatellite instability (MSI)

• African ancestry populations experience disproportionate mortality burdens, with African Americans showing the highest CRC mortality rates among all racial groups and approximately 10% higher likelihood of KRAS mutations that confer therapeutic resistance and elevated mortality

• Early-onset colorectal cancer (EOCRC) patients under 50 years represent a growing population with more aggressive disease features, higher rates of widespread metastases, and require more tailored treatment approaches despite undergoing intensified therapies

• Patients with suboptimal biomarker testing constitute a significant unmet need, with only 35% of advanced cancer patients receiving molecular testing despite clinical guidelines recommending biomarker assessment to identify targeted therapy eligibility

• African populations, particularly in Mozambique, face critical gaps with CRC manifesting at younger ages and advanced stages, combined with scarce clinical management strategies leading to high mortality rates and limited molecular characterization data

• HER2-positive, RAS wild-type metastatic patients represent an underserved population with emerging targeted therapy options showing promise, as demonstrated by tucatinib plus trastuzumab achieving 39.3% objective response rates in chemotherapy-refractory cases

Designing the Labcorp-Alliance Trial for CRC Genetic Access

Multiple large-scale studies have established comprehensive design parameters for colorectal cancer trials across metastatic, adjuvant, and neoadjuvant settings. These trials range from single-center studies with hundreds of patients to international multi-center efforts enrolling thousands, with follow-up periods extending beyond 8 years in pivotal studies.

Study Design Parameters:

• Phase III trials in metastatic colorectal cancer published between 1980-2015 included 114 trials eligible for net health benefit score calculation, with recent studies incorporating molecular stratification for KRAS wild-type and HER2-positive populations

• The landmark EORTC Intergroup Trial 40983 recruited 364 patients from 78 hospitals across Europe, Australia, and Hong Kong using 1:1 randomization with minimization adjusting for center, risk score, and previous adjuvant chemotherapy

• Large database studies utilized the ACCENT database examining 25,291 patients with stage II-III colon carcinoma and the National Cancer Data Base with 7,794 patients receiving adjuvant chemotherapy following resection

• Recent targeted therapy trials focus on specific molecular subsets, including HER2-positive digestive cancers (NCT03185988) with 21 patients and brivanib combination studies with 750 randomized patients

• Meta-analyses incorporate data from 15 comparative studies with over 4,700 patients for total neoadjuvant therapy evaluation and systematic reviews of 166 phase III randomized controlled trials

Primary Endpoints:

• Overall survival (OS) serves as the gold standard primary endpoint, particularly in adjuvant settings where 92.0% of approved agents were based on trials with positive OS outcomes

• Progression-free survival (PFS) and disease-free survival (DFS) are established as primary endpoints for metastatic and adjuvant studies respectively, though correlation between PFS and OS requires clear validation

• Objective response rate functions as the primary endpoint in phase II studies, including HER2-targeted therapy trials achieving 33.3% objective response rates

• Complete pathological response represents a key primary endpoint in neoadjuvant studies, with total neoadjuvant therapy achieving 22.3% compared to 14.2% with standard chemoradiotherapy

Secondary Endpoints:

• Treatment-related adverse events (TRAEs) with specific focus on grade 3-4 toxicities, treatment discontinuations, and dose modifications, though 59.0% of trials fail to provide statistical comparison of adverse event rates

• Quality of life measures, cost-effectiveness ratios, and patient-reported outcomes including anxiety, subjective knowledge, and treatment preferences in decision aid studies

• Molecular and metabolomic biomarker assessments, including 29 metabolites distinguishing patients with treatment-induced hypertension and deep learning models for tumor-stroma ratio prediction using preoperative CT imaging

• Time-based efficacy measures including time to tumor progression, median time to disease progression, and duration of treatment response across first- and second-line therapies

How Genetic Insights Are Reshaping Colorectal Cancer Care

The treatment landscape for colorectal cancer has undergone significant evolution over the past five years, with notable advances in precision medicine, combination therapies, and novel targeted approaches. Recent phase I trials for refractory CRC patients have demonstrated promising outcomes with median overall survival of 16.8 months and 12-month survival rates of 58%. Multivariable analyses have identified key prognostic factors including primary tumor resection, low lymphocyte/monocyte ratios, and left-sided tumors, which are now informing treatment decisions. The emergence of drug repurposing strategies has gained momentum as a cost-effective approach to accelerate therapeutic development, while consensus molecular subtype classification has enabled more precise patient stratification for personalized treatment selection.

Combination therapy optimization has yielded meaningful clinical improvements, particularly with modified dosing regimens. Biweekly TAS-102 and bevacizumab therapy has shown enhanced tolerability profiles with reduced grade 3/4 neutropenia rates of 15.9% compared to approximately 50% with conventional dosing, while maintaining efficacy with median progression-free survival of 4.6 months. The FOLFIRI and aflibercept combination in second-line treatment has demonstrated median overall survival of 11.6 months with improved response rates compared to historical controls. Novel targeted therapies have expanded treatment options for specific molecular subsets, including divarasib for KRAS G12C-mutant tumors showing 29.1% confirmed response rates, and encorafenib combinations for BRAF V600E-mutated cancers providing clinically meaningful survival benefits.

Immunotherapy advances have extended beyond the traditional mismatch repair-deficient population, though challenges remain for the broader microsatellite stable patient cohort. The combination of lenvatinib plus pembrolizumab in the LEAP-005 study achieved 14% objective response rates in previously treated advanced CRC patients, while immune checkpoint inhibitors including pembrolizumab, nivolumab, and ipilimumab have gained approval for select patient populations. Emerging therapeutic modalities under investigation include CAR-T cell therapy, bispecific T-cell engagers, tumor-infiltrating lymphocytes, and oncolytic virus therapy. Despite these advances, treatment disparities in elderly patients persist, with reduced chemotherapy utilization in those over 80 years, though survival outcomes have shown improvements in rectal cancer management through enhanced multimodal approaches.

Advancing Hereditary CRC Testing: A National Collaborative Push

Colorectal cancer remains a significant public health challenge, and a notable proportion of cases, estimated at 5-10%, are attributed to inherited genetic mutations, primarily Lynch syndrome and familial adenomatous polyposis. Identifying these hereditary predispositions is paramount, not only for the newly diagnosed patient but also for their at-risk first-degree relatives, enabling targeted surveillance and early intervention to reduce cancer incidence and mortality.

The current collaboration between Labcorp, the Alliance for Clinical Trials in Oncology, and the National Cancer Institute marks a pivotal effort to bridge existing gaps in genetic testing access and utilization. While universal screening for Lynch syndrome in newly diagnosed CRC patients is recommended, its widespread implementation has faced logistical hurdles, including suboptimal referral rates and challenges in ensuring family members undergo cascade testing. This national study directly addresses these issues by expanding access to comprehensive multigene panel testing and rigorously evaluating how direct outreach by healthcare providers can improve participation in cascade testing.

For Labcorp, this exclusive partnership with a major NCI-sponsored initiative represents a strategic opportunity to solidify its leadership in genomic diagnostics, potentially setting a benchmark for future large-scale precision oncology programs. The insights gained into effective provider outreach models could inform national guidelines, fostering better family engagement and increasing the currently low uptake rates of genetic testing among at-risk relatives. Furthermore, understanding how multigene panel results influence treatment and care decisions will provide crucial evidence for integrating advanced genomic profiling more deeply into clinical practice.

However, several risks must be carefully navigated. Historical data indicates that even with increased awareness and access, the uptake of genetic testing by at-risk relatives can be low. Moreover, disparities in genetic testing utilization persist, particularly among minority-serving physicians, highlighting the need for culturally sensitive and equitable outreach strategies. Ensuring that patients and families receive adequate, understandable information to make informed decisions about genetic testing and subsequent surveillance remains critical. This study has the potential to not only enhance our understanding of hereditary CRC but also to model effective, equitable approaches to genomic medicine, ultimately improving outcomes for countless families.